Creoscg Obtains Domestic Patent for Recombinant VSV-Based COVID-19 Vaccine
Predicted impact: Low
Domestic patent for a COVID-19 vaccine platform; early-stage and small for CreoSG.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.